AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23378769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily
Number of subjects: 178
Study 23378769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 21195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Carthami-Semen (CS) acupuncture point injection
Number of subjects: 40
Study 21195291 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) acupuncture point injection
Number of subjects: 40
Study 19446152 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (300 mg loading dose, 75 mg/d maintenance dose)
Number of subjects: 44
Study 19446152 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate (300 mg loading dose, 75 mg/d maintenance dose)
Number of subjects: 44
Study 19446152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both clopidogrel preparations
Number of subjects: 44
Study 16805721 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 16805721 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn insulin (NPH)
Number of subjects: 0
Study 16805721 — intervention group
Group type: COMPARATOR
Intervention: Insulin ultralente
Number of subjects: 0
Study 15628250 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Relief gel with sonophoresis
Number of subjects: 130
Study 15628250 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound with standard gel
Number of subjects: 130
Study 11316646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg NCS
Number of subjects: 14
Study 11316646 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg NCS
Number of subjects: 14
Study 11316646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11316646 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 14
Study 9252710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan administration
Number of subjects: 0
Study 7514863 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy
Number of subjects: 12
Study 2531608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg p.o.)
Number of subjects: 6
Study 2531608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg p.o.)
Number of subjects: 6
Study 31090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (HRU)
Number of subjects: 302
Study 31090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy utilization (STU)
Number of subjects: 302
Study 31090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Common reasons for hospitalization
Number of subjects: 302
Study 31090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Common reasons for surgery
Number of subjects: 302
Study 31090212 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly prescribed drugs
Number of subjects: 302
Study 28854067 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus ipilimumab
Number of subjects: 956
Study 28854067 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 956
Study 26305052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 75 mg twice daily for 30 days
Number of subjects: 20
Study 26305052 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 30 days
Number of subjects: 20
Study 23686786 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine/Ephedrine (200 mg caffeine/20 mg ephedrine t.i.d.)
Number of subjects: 90
Study 23686786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Leptin A‐200 and Caffeine/Ephedrine (Leptin A‐200 20 mg q.d. + Caffeine/Ephedrine)
Number of subjects: 90
Study 23686786 — intervention group
Group type: COMPARATOR
Intervention: Leptin A‐200 (20 mg q.d.)
Number of subjects: 90
Study 21320959 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfoveal serous retinal detachment (SRD) group
Number of subjects: 98
Study 21320959 — intervention group
Group type: COMPARATOR
Intervention: Control group (without SRD)
Number of subjects: 98
Study 18692817 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing target cytokines
Number of subjects: 0
Study 17159824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (2 mg daily)
Number of subjects: 45
Study 17159824 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (0.05 mg daily)
Number of subjects: 45
Study 17159824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and transdermal)
Number of subjects: 45
Study 14971862 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 36
Study 14971862 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 36
Study 11093452 — intervention group
Group type: COMPARATOR
Intervention: Motivated simulator group (financially incentivized to simulate FM)
Number of subjects: 27
Study 11093452 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (healthy volunteers)
Number of subjects: 27
Study 11093452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic FM subjects
Number of subjects: 27
Study 11093452 — intervention group
Group type: COMPARATOR
Intervention: Blinded examiners using American College of Rheumatology criteria for FM
Number of subjects: 27
Study 11093452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 27
Study 9383183 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan (plus 12.5 mg hydrochlorothiazide if necessary)
Number of subjects: 898
Study 9383183 — intervention group
Group type: COMPARATOR
Intervention: 5 mg amlodipine (increased to 10 mg if necessary)
Number of subjects: 898
Study 1490530 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment
Number of subjects: 144
Study 1490530 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment
Number of subjects: 144
Study 3883671 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 15
Study 3883671 — intervention group
Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 15
Study 31072935 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 140
Study 31072935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29397354 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin 480 mg taken orally every 12 hours
Number of subjects: 282
Study 29397354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 29397354 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin
Number of subjects: 282
Study 29397354 — intervention group
Group type: EXPERIMENTAL
Intervention: Napabucasin (in pSTAT3-positive patients)
Number of subjects: 282
Study 29397354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in pSTAT3-positive patients)
Number of subjects: 282
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of antiepileptic drugs (AEDs)
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytherapy >1 AED
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >12 years
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian ethnicity
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure time 30-60 min/day
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure time <30 min/day
Number of subjects: 244
Study 27378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 244
Study 24930587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyll-a photodynamic therapy (8 treatment sessions over 4 weeks)
Number of subjects: 24
Study 24930587 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode phototherapy (control)
Number of subjects: 24
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (3 doses)
Number of subjects: 1773
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (2 doses)
Number of subjects: 1773
Study 22520135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (overall efficacy)
Number of subjects: 1773
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (second year of life)
Number of subjects: 1773
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (first year of life)
Number of subjects: 1773
Study 22520135 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (three-dose schedule)
Number of subjects: 1773
Study 20623434 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven‐eyelet lacings
Number of subjects: 14
Study 20623434 — intervention group
Group type: COMPARATOR
Intervention: Regular six‐eyelet technique
Number of subjects: 14
Study 20623434 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually chosen special seven‐eyelet lacings
Number of subjects: 14
Study 17659990 — intervention group
Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 58
Study 17659990 — intervention group
Group type: COMPARATOR
Intervention: Butterbur root extract
Number of subjects: 58
Study 17659990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15795719 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine infused over 15 minutes
Number of subjects: 180
Study 15795719 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine infused over 60 minutes
Number of subjects: 180
Study 12420826 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of regular supplemental human interaction (20 min/d, 5 d/wk, for 8 weeks)
Number of subjects: 40
Study 12420826 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium diet
Number of subjects: 40
Study 12420826 — intervention group
Group type: COMPARATOR
Intervention: Typical maintenance-type diet
Number of subjects: 40
Study 10328384 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral suture fixation
Number of subjects: 153
Study 10328384 — intervention group
Group type: COMPARATOR
Intervention: Out-of-the-bag implantation
Number of subjects: 153
Study 10328384 — intervention group
Group type: COMPARATOR
Intervention: In-the-bag implantation
Number of subjects: 153
Study 8787036 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting haloperidol (LA HAL)
Number of subjects: 31
Study 8787036 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of haloperidol
Number of subjects: 31
Study 1659934 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 180
Study 1659934 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 180
Study 1659934 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 180
Study 1659934 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 180
Study 1659934 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 180
Study 6356911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (Cinopal) at doses of 600 to 1,000 mg daily
Number of subjects: 155
Study 6356911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (Cinopal)
Number of subjects: 155
Study 6356911 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, Indomethacin, Placebo
Number of subjects: 155
Study 31436125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model of synaptic plasticity in the SCN network
Number of subjects: 0
Study 31436125 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cycles with periods within 2.5 to 3 h of the population period
Number of subjects: 0
Study 31436125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low variability of periods between oscillators
Number of subjects: 0
Study 31436125 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater between-cell variability
Number of subjects: 0
Study 28741785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg per day) from 11-14 until 36 weeks' gestation
Number of subjects: 25797
Study 28741785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25797
Study 28741785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined first-trimester screening for preterm PE
Number of subjects: 25797
Study 26911397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence therapy (six sessions in addition to usual care)
Number of subjects: 134
Study 26911397 — intervention group
Group type: COMPARATOR
Intervention: Usual psychiatric care alone
Number of subjects: 134
Study 24500453 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) - one pre and six postoperative sessions
Number of subjects: 57
Study 24500453 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 57
Study 22676459 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 63
Study 22676459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19899321 — intervention group
Group type: EXPERIMENTAL
Intervention: noMR group (n = 40) - only an intubation dose of cisatracurium (0.15 mg kg(‐1)) was administered
Number of subjects: 80
Study 19899321 — intervention group
Group type: COMPARATOR
Intervention: MR group (n = 40) - continuous infusion of muscle relaxant added to the intubation dose
Number of subjects: 80
Study 19899321 — intervention group
Group type: EXPERIMENTAL
Intervention: noMR group (n = 40) - more remifentanil was used (p = 0.001)
Number of subjects: 80
Study 19899321 — intervention group
Group type: COMPARATOR
Intervention: Both groups - post-operative characteristics and complication rates
Number of subjects: 80
Study 17642451 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-flow based self-management (Group A, n=30)
Number of subjects: 60
Study 17642451 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Group B, n=30)
Number of subjects: 60
Study 15100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine at 50 ng/ml plasma concentration
Number of subjects: 0
Study 15100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine at 100 ng/ml plasma concentration
Number of subjects: 0
Study 15100698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11246934 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 12 weeks (study Alpha)
Number of subjects: 119
Study 11246934 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 24 weeks (study Omega)
Number of subjects: 119
Study 9674458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin, 400 mg on day 1, then 200 mg once daily for 10 days
Number of subjects: 798
Study 9674458 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin, 400 mg twice daily for 10 days
Number of subjects: 798
Study 9674458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 798
Study 9674458 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 798
Study 8033429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous immune globulin (IVIG)
Number of subjects: 0
Study 8033429 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy and/or relapse
Number of subjects: 0
Study 2735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group intervention
Number of subjects: 374
Study 2735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Home study intervention
Number of subjects: 374
Study 2735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention models
Number of subjects: 374
Study 29652544 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-guided slow breathing (DGB) at 5 breaths/min (n = 13)
Number of subjects: 23
Study 29652544 — intervention group
Group type: COMPARATOR
Intervention: Sham device breathing at normal rates of 14 breaths/min (n = 10)
Number of subjects: 23
Study 28577670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10921
Study 28577670 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10921
Study 26031292 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar-simulated ultraviolet light (SSL) irradiation
Number of subjects: 24
Study 23642943 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2 g per day, single dosage of two 1 g pearls)
Number of subjects: 124
Study 23642943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 placebo soft gels)
Number of subjects: 124
Study 21091683 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nadifloxacin 1% cream
Number of subjects: 86
Study 21091683 — intervention group
Group type: COMPARATOR
Intervention: Topical erythromycin 4% gel
Number of subjects: 86
Study 18206946 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm treatment following pretreatment with antimuscarinics and/or holding exercises
Number of subjects: 149
Study 18206946 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving just alarm treatment
Number of subjects: 149
Study 18206946 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A and B with holding exercises
Number of subjects: 149
Study 18206946 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment
Number of subjects: 149
Study 18206946 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 8 years
Number of subjects: 149
Study 16685128 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 2330
Study 16685128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2330
Study 15335092 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Carbamide peroxide (CP)
Number of subjects: 90
Study 15335092 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% Carbamide peroxide (CP)
Number of subjects: 90
Study 15335092 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 90
Study 21407958 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 21407958 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 9333973 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic Horseback‐Riding‐Therapy (OHRT)
Number of subjects: 16
Study 8500515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg bumethanide at 0800 and 1200 (treatment 1)
Number of subjects: 8
Study 8500515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2)
Number of subjects: 8
Study 8500515 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3)
Number of subjects: 8
Study 3014018 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta ser
Number of subjects: 47
Study 3014018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29615003 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR + Ara-C (Ara-C group)
Number of subjects: 66
Study 29615003 — intervention group
Group type: COMPARATOR
Intervention: DNR (no-Ara-C group)
Number of subjects: 66
Study 27584567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous β-blockers
Number of subjects: 1149
Study 24215858 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 355
Study 24215858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 355
Study 24215858 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 355
Study 24215858 — intervention group
Group type: COMPARATOR
Intervention: Usual Activity (Control)
Number of subjects: 355
Study 22638012 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28
Study 22638012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20815080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 0
Study 20815080 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (PDN)
Number of subjects: 0
Study 19128246 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-releasing stents
Number of subjects: 10
Study 19128246 — intervention group
Group type: COMPARATOR
Intervention: Placebo stents
Number of subjects: 10
Study 16787141 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF drugs
Number of subjects: 0
Study 12756363 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 0
Study 12756363 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 0
Study 12756363 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair at diameter <5.5 cm
Number of subjects: 0
Study 12756363 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair at larger diameter
Number of subjects: 0
Study 11014755 — intervention group
Group type: EXPERIMENTAL
Intervention: AARN rucksack
Number of subjects: 9
Study 11014755 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rucksack
Number of subjects: 9
Study 11014755 — intervention group
Group type: COMPARATOR
Intervention: Unloaded walking
Number of subjects: 9
Study 8781854 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 kJ.24 h‐1 additional energy in course A
Number of subjects: 8
Study 8781854 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous aerobic physical activities
Number of subjects: 8
Study 8781854 — intervention group
Group type: COMPARATOR
Intervention: Control response
Number of subjects: 8
Study 1595785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin plus low-dose aspirin
Number of subjects: 20
Study 1595785 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg daily) plus low-dose aspirin
Number of subjects: 20
Study 3883732 — intervention group
Group type: EXPERIMENTAL
Intervention: oral molsidomine (Corvaton, 6 mg/day)
Number of subjects: 25
Study 29490959 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 3 weeks (taper arm)
Number of subjects: 0
Study 29490959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal arm)
Number of subjects: 0